Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Free Radic Biol Med ; 213: 266-273, 2024 03.
Artigo em Inglês | MEDLINE | ID: mdl-38278309

RESUMO

Yellow fever (YF) presents a wide spectrum of severity, with clinical manifestations in humans ranging from febrile and self-limited to fatal cases. Although YF is an old disease for which an effective and safe vaccine exists, little is known about the viral- and host-specific mechanisms that contribute to liver pathology. Several studies have demonstrated that oxidative stress triggered by viral infections contributes to pathogenesis. We evaluated whether yellow fever virus (YFV), when infecting human hepatocytes cells, could trigger an imbalance in redox homeostasis, culminating in oxidative stress. YFV infection resulted in a significant increase in reactive oxygen species (ROS) levels from 2 to 4 days post infection (dpi). When measuring oxidative parameters at 4 dpi, YFV infection caused oxidative damage to lipids, proteins, and DNA, evidenced by an increase in lipid peroxidation/8-isoprostane, carbonyl protein, and 8-hydroxy-2'-deoxyguanosine, respectively. Furthermore, there was a significant reduction in the activity of the antioxidant enzymes superoxide dismutase (SOD) and glutathione peroxidase (GPx), in addition to a reduction in the ratio of reduced to oxidized glutathione (GSH/GSSG), indicating a pro-oxidant environment. However, no changes were observed in the enzymatic activity of the enzyme catalase (CAT) or in the gene expression of SOD isoforms (1/2/3), CAT, or GPx. Therefore, our results show that YFV infection generates an imbalance in redox homeostasis, with the overproduction of ROS and depletion of antioxidant enzymes, which induces oxidative damage to cellular constituents. Moreover, as it has been demonstrated that oxidative stress is a conspicuous event in YFV infection, therapeutic strategies based on antioxidant biopharmaceuticals may be new targets for the treatment of YF.


Assuntos
Antioxidantes , Febre Amarela , Humanos , Antioxidantes/metabolismo , Espécies Reativas de Oxigênio/metabolismo , Vírus da Febre Amarela/metabolismo , Glutationa/metabolismo , Estresse Oxidativo , Oxirredução , Catalase/genética , Catalase/metabolismo , Superóxido Dismutase/genética , Superóxido Dismutase/metabolismo , Dissulfeto de Glutationa/metabolismo , Hepatócitos/metabolismo , Peroxidação de Lipídeos , Glutationa Peroxidase/metabolismo , 8-Hidroxi-2'-Desoxiguanosina/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA